ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 439

Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18)

Ditte Reker1, Christian S. Thudium2, Anne Sofie Siebuhr3, Thorbjørn Gantzel4, Christoph Ladel5, Martin Michaelis5, Morten A. Karsdal2, Anne Gigout5 and Anne C. Bay-Jensen2, 1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 4cOrthopedic Surgery Unit, Gentofte Hospital, Hellerup, Denmark, 5Merck KGaA, Darmstadt, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cartilage, growth factors, osteoarthritis and treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Osteoarthritis – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sprifermin, a truncated form of human fibroblast growth factor 18 (FGF18), is being investigated as a potential cartilage and disease-modifying OA drug. In vitro, Sprifermin induces chondrocyte proliferation and extracellular matrix (ECM) production. Here, we characterized the ECM remodeling of human knee OA articular cartilage in response to long-term Sprifermin treatment.

Methods: Full depth articular cartilage explants from OA patients (npatients=11) were cultured for 70 days. Freshly prepared media with either Sprifermin (900, 450, 225 ng/mL), FGF18 (450 ng/mL), IGF-1 (100 ng/mL, positive control) or placebo formulation (negative control) was added once weekly (nexplants/treatment/patient=2). Metabolic activity was measured weekly by AlamarBlue. Biomarkers of ECM remodelling were quantified in conditioned media using well-described ELISAs; exPro-C2 reflecting type II collagen formation and exAGNx1 reflecting aggrecanase-mediated aggrecan degradation. Data  were baseline-corrected and normalized to placebo for each individual patient and reported as mean ± standard errors of the mean (SEM).

Results: In human OA articular cartilage cultured ex vivo, the positive control IGF-1 induced ProC2 and increased metabolic activity in all patient explants as well. All investigated doses of Sprifermin and FGF18 continuously increased metabolic activity compared to placebo over the 70 days of treatment (fig. 1A). The aggrecan degradation biomarker exAGNx1 was increased by the investigated doses of Sprifermin and FGF18 as compared to placebo (fig. 1B). exAGNX1 release peaked at 21 and then  gradually decreased in presence of Sprifermin and FGF18, indicating a shift of a catabolic to an anabolic phenotype as cause of treatment. Type II collagen formation, measured by exProC2, was initially (day 7-28) decreased by Sprifermin and FGF18 compared to placebo, but from day 35 to 70 exProC2 increased in a dose dependent manner, with sprifermin superior to FGF-18 (fig. 1C). The increase in exProC2 release from Sprifermin (900 ng/mL)-treated explants were 1.5-fold of placebo at day 49.

Conclusion: The data indicate that human knee OA articular cartilage explants increase their metabolic activity and formation of type II collagen in response to long-term treatment with Sprifermin and FGF18. The induction of cartilage formation is preceded by cartilage degradation, indicating that a catabolic process is needed to make room of proliferation of chondrocyte and renewal of cartilage (fig. 2).

Figure 2. Schematic illustration of sprifermin effects on articular cartilage


Disclosure: D. Reker, Nordic Bioscience, 3; C. S. Thudium, Nordic Biocience, 3; A. S. Siebuhr, Nordic Bioscience, 3; T. Gantzel, None; C. Ladel, Merck KGaA, 3; M. Michaelis, Merck KGaA, 3; M. A. Karsdal, Nordic Bioscience, 1, 3; A. Gigout, Merck KGaA, 3; A. C. Bay-Jensen, Nordic Bioscience, 1, 3,IMI APPROACH, 2.

To cite this abstract in AMA style:

Reker D, Thudium CS, Siebuhr AS, Gantzel T, Ladel C, Michaelis M, Karsdal MA, Gigout A, Bay-Jensen AC. Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/articular-cartilage-from-osteoarthritis-patients-shows-extracellular-matrix-remodeling-over-the-course-of-treatment-with-sprifermin-recombinant-human-fibroblast-growth-factor-18/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/articular-cartilage-from-osteoarthritis-patients-shows-extracellular-matrix-remodeling-over-the-course-of-treatment-with-sprifermin-recombinant-human-fibroblast-growth-factor-18/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology